• Publications
  • Influence
Different embryo-fetal toxicity effects for three VLA-4 antagonists.
  • F. Crofts, M. Pino, R. Clark
  • Medicine, Biology
    Birth defects research. Part B, Developmental and…
  • 1 April 2004
Dramatic differences in teratogenic potential were observed: IVL745 was not ter atogenic, HMR1031 caused slight embryo-fetal effects at maternally-toxic doses, and IVL984 was a potent teratogen at doses where direct maternal toxicity was limited to abortions in rabbits.
Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
The critical period for IVL984 in the rat, GD 10 to 11, corresponds to the expression of alpha-4 integrin on the chorion and VCAM-1 on the allantois and myocardium as well as chorioallantoic fusion and formation of the spiral septum.
Epidermal growth factor prevents thallium(I)- and thallium(III)-mediated rat pheochromocytoma (PC12) cell apoptosis
EGF partially prevents the noxious effects of Tl by preventing the sustained activation of MAPKs signaling cascade that lead cells to apoptosis and point to p38 as a key mediator of TL(III)-induced PC12 cell apoptosis.
Tl(I) and Tl(III) alter the expression of EGF‐dependent signals and cyclins required for pheochromocytoma (PC12) cell‐cycle resumption and progression
Results indicate that Tl(I) promoted cell proliferation in both EGF− and EGF+ cells, which may be related to the toxic effects of this cation in PC12 cells.
Soluble guanylyl cyclase α1 subunit is a key mediator of proliferation, survival, and migration in ECC-1 and HeLa cell lines
The results show that sGCα1 mediated cell proliferation, survival, and migration in ECC-1 and HeLa cells and suggest that s GCα1 can not only mediate E2-tumour promoting effects but can also be involved in hormone-independent tumour progression.
Soluble Guanylyl Cyclase Alpha1 Subunit: A New Marker for Estrogenicity of Endocrine Disruptor Compounds
Evidence is provided that the in vitro sGCα1 protein assay may be a very sensitive and powerful tool to identify compounds with estrogenic activity, which could improve current mammalian‐based screening methods.